TFF Pharmaceuticals (NASDAQ:TFFP) Price Target Cut to $4.00 by Analysts at HC Wainwright

TFF Pharmaceuticals (NASDAQ:TFFP – Get Rating) had its price objective trimmed by HC Wainwright from $22.00 to $4.00 in a research note released on Thursday morning, The Fly reports.

Separately, Jonestrading assumed coverage on TFF Pharmaceuticals in a report on Wednesday, March 22nd. They set a buy rating and a $7.00 target price for the company.

TFF Pharmaceuticals Stock Down 7.1 %

Shares of NASDAQ TFFP opened at $0.55 on Thursday. TFF Pharmaceuticals has a 1-year low of $0.48 and a 1-year high of $6.73. The business’s fifty day moving average price is $0.66 and its two-hundred day moving average price is $0.89.

Insider Buying and Selling

In other TFF Pharmaceuticals news, CEO Harlan F. Weisman acquired 150,000 shares of TFF Pharmaceuticals stock in a transaction that occurred on Friday, March 10th. The stock was purchased at an average cost of $0.88 per share, with a total value of $132,000.00. Following the purchase, the chief executive officer now owns 214,615 shares in the company, valued at $188,861.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders acquired 177,000 shares of company stock valued at $153,780. Corporate insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On TFF Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in TFFP. UBS Group AG grew its holdings in TFF Pharmaceuticals by 13.8% in the 1st quarter. UBS Group AG now owns 129,780 shares of the company’s stock valued at $89,000 after buying an additional 15,709 shares during the last quarter. Sigma Planning Corp increased its stake in shares of TFF Pharmaceuticals by 53.8% in the 1st quarter. Sigma Planning Corp now owns 155,191 shares of the company’s stock valued at $106,000 after buying an additional 54,300 shares during the period. Gagnon Securities LLC increased its stake in shares of TFF Pharmaceuticals by 255.3% in the 1st quarter. Gagnon Securities LLC now owns 221,207 shares of the company’s stock valued at $152,000 after buying an additional 158,943 shares during the period. AIGH Capital Management LLC acquired a new stake in shares of TFF Pharmaceuticals in the 4th quarter valued at $1,826,000. Finally, DRW Securities LLC acquired a new stake in shares of TFF Pharmaceuticals in the 4th quarter valued at $1,050,000. 16.46% of the stock is owned by hedge funds and other institutional investors.

TFF Pharmaceuticals Company Profile

(Get Rating)

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.